UCL Institute of Neurology



UCL success at Dementia Research Leaders awards

We are delighted to announce the success of UCL Institute of Neurology researchers at the Alzheimer's Society Dementia Research Leaders awards, which were presented at the Alzheimer's Society Research conference on June 30th 2016.

Publication date:

How Huntington’s could help unlock the challenges of dementia

Professor Sarah Tabrizi, Director of the Huntington’s Disease Centre, UCL Institute of Neurology, gave an inspiring keynote speech at Google’s Zeitgeist. Zeitgeist is a high-profile gathering of business leaders and thinkers. Professor Tabrizi’s speech focused on how research on a genetic dementia like Huntington’s disease may not only offer hope to those who carry the Huntington's gene but also unlock treatments for other more complex dementias such as Alzheimer’s disease.

Publication date:

Exploration of dementia announced as second project of The Hub at Wellcome Collection

A group exploring dementia and the arts have been invited to take up the 2016-2018 residency in The Hub at Wellcome Collection, a flagship space and resource for interdisciplinary projects exploring health and wellbeing. Bringing together a rich network including scientists, artists, clinicians, public health experts and broadcasters, the group will examine and challenge perceptions of dementia through scientific and creative experimentation. They have been awarded £1 million to develop the project over two years.

Publication date:

Major Wellcome Trust award to UCL boosts Huntington’s disease research

UCL today announced that a team of researchers from UCL and the University of Cambridge led by Professor Sarah Tabrizi, Director of the Huntington’s Disease Centre, UCL Institute of Neurology, have been granted a prestigious Wellcome Trust Collaborative Award in one of the largest investments in Huntington’s Disease (HD) ever given by a public funding body in the UK. The 5-year, £3.4 million investment will support research to help our understanding of disease mechanisms in HD and, importantly, their response to treatment. This valuable work will in turn provide insights into other more common neurodegenerative diseases.

Publication date:

UCL launches free online dementia course

UCL Institute of Neurology has today announced a free four-week online course “The Many Faces of Dementia” aiming to provide valuable insights into dementia through the stories, symptoms and science behind four less common diagnoses. The interactive MOOC (massive open online course) features interviews with world-leading experts, people with dementia and their families as well as articles and discussion.

Publication date:

UCL Institute of Neurology hosts inaugural Ada Lovelace Day event

The UCL Institute of Neurology invited a group of teenage girls from Camden’s Parliament Hill School to visit on 13 October as part of an initiative to encourage more to pursue studies in science, technology, engineering and mathematics (STEM).

Publication date:

First human trial for innovative new drug in development to treat Huntington’s disease

Patients in London are being dosed for the first time with an experimental drug for Huntington’s disease. This breakthrough could be one of the most important developments since the gene for Huntington’s disease was discovered in 1993. The trial of the revolutionary new ‘gene silencing’ treatment is being led by scientists at UCL’s Institute of Neurology. The first patients received doses of the drug at the Leonard Wolfson Experimental Neurology Centre at UCLH's National Hospital for Neurology and Neurosurgery.

Publication date:

UCL and UK supermarkets unite to beat dementia

UK supermarkets Iceland, Asda, Morrisons and Waitrose have today pledged funds from the new levy on single-use carrier bags to support the construction of a new world class dementia research centre at UCL.

Publication date:

Possible evidence for human transmission of Alzheimer’s pathology

Amyloid beta pathology in the grey matter and blood vessel walls characteristic of Alzheimer’s disease (AD) and the related cerebral amyloid angiopathy (CAA) is observed in the brains of deceased patients who acquired Creutzfeldt–Jakob disease (CJD) following treatment with prion-contaminated human growth hormone.

Publication date:

Compensation in Huntington’s disease

A new measure has been developed which can explicitly characterise compensation in Huntington’s disease (HD) gene-carriers prior to clinical diagnosis. Publishing in EBioMedicine, the research team working on the study hope that identifying patterns of compensation in preclinical HD will not only improve understanding of neural mechanisms underlying HD pathology, but also provide potential targets that can be used in the testing of HD therapeutics.

Publication date:

Natural genetic variation gives complete resistance in prion diseases

Researchers at the Medical Research Council’s Prion Unit at the UCL Institute of Neurology have identified a naturally occurring variant of the human prion protein that produces resistance to prion diseases such as Creutzfeldt-Jakob disease (CJD). The findings, published in Nature, could give important insight into other human brain diseases that lead to dementia.

Publication date:

Professor Tabrizi and Professor Price elected to Fellowship of the Academy of Medical Sciences.

Professor Sarah Tabrizi (Department of Neurodegenerative Diseases, UCL Institute of Neurology and Honorary Consultant Neurologist at the National Hospital of Neurology and Neurosurgery) and Professor Cathy Price (Wellcome Trust Centre for Neuroimaging, UCL Institute of Neurology) have been recognised for their contribution to the advancement of medical science by election to the Fellowship of the Academy of Medical Sciences.

Publication date: